Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab-Reference-Cited by-同舟云学术

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

Published:2019-02 Issue:2 Volume:27 Page:92-100
ISSN:1541-2016
Container-title:Applied Immunohistochemistry & Molecular Morphology
language:en
Short-container-title:

Author:

Vennapusa Bharathi,Baker Brian,Kowanetz Marcin,Boone Jennifer,Menzl Ina,Bruey Jean-Marie,Fine Gregg,Mariathasan Sanjeev,McCaffery Ian,Mocci Simonetta,Rost Sandra,Smith Dustin,Dennis Eslie,Tang Szu-Yu,Damadzadeh Bita,Walker Espen,Hegde Priti S.,Williams J. Andrew,Koeppen Hartmut,Boyd Zachary

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Medical Laboratory Technology,Histology,Pathology and Forensic Medicine

Reference20 articles.

1. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1;Chen;Clin Cancer Res,2012

2. Oncology meets immunology: the cancer-immunity cycle;Chen;Immunity,2013

3. PD-L2 is a second ligand for PD-1 and inhibits T cell activation;Latchman;Nat Immunol,2001

4. B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma;Matsumoto;Biochem Biophys Res Commun,2008

5. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions;Akbari;Mucosal Immunol,2010

Cited by 149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pan‐cancer evaluation of tumor‐infiltrating lymphocytes and programmed cell death protein ligand‐1 in metastatic biopsies and matched primary tumors;The Journal of Pathology;2024-07-29

2. PD-L1 Expression in Paired Samples of Rectal Cancer;Cancers;2024-07-21

3. Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials;Molecular Oncology;2024-07-08

4. Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art;International Journal of Molecular Sciences;2024-06-11

5. Assessing the relationship between tumor-infiltrating lymphocytes and PD-L1 expression in triple negative breast cancer: Identifying optimal TILs cut-off value for pathologic reporting;Annals of Diagnostic Pathology;2024-06